Drugs / Dryvax
Dryvax
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT00082446 | May 2004 → Aug 2007 | smallpox | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT00042094 | Mar 2002 → Mar 2003 | smallpox | DynPort Vaccine Company LLC, A GDIT Company | Completed | No outcome recorded |
| Phase 1 | NCT00000767 | ? → Jul 1996 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT00068198 | ? → Nov 2004 | smallpox | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00437021 | Apr 2007 → Apr 2009 | smallpox | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT00032708 | Apr → Nov 2004 | smallpox | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT00050505 | Oct 2002 → Dec 2003 | smallpox | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT00026611 | ? → Dec 2001 | smallpox | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 1/2 | NCT00133575 Background | Oct 2005 → Apr 2008 | smallpox | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT00053495 Comparator | Jan → Jun 2003 | smallpox | Emergent BioSolutions | Completed | No outcome recorded |
| Phase 2 | NCT00053508 Comparator | Sep 2002 → Mar 2003 | smallpox | Sanofi Pasteur, a Sanofi Company | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dryvax | “Dryvax®: 0.25 mL of vaccine will be administered by the standard route of scarification using a bifurcated needle on day 112 for Groups A, B, C, D and F.” NCT00082446 ↗11“Group B receives priming with control vaccine (DryVax), followed by boosting with an appropriate placebo.” NCT00000767 ↗ “Dryvax® smallpox vaccine administered at approximately day 180, dosage 10\^8 pfu/ml.” NCT00133575 ↗ “Dryvax undiluted. Cohort A receives undiluted dose of Dryvax vaccine” NCT00050505 ↗ “Dryvax® Vaccinia Vaccine” NCT00437021 ↗ “Dryvax®” NCT00053495 ↗ |
| Known as | brand name = Dryvax | “brand name = Dryvax” NCT00053508 ↗ |
| Known as | vaccinia virus | “Because of the limited amount of Dryvax vaccine (vaccinia virus) against smallpox, this study will look at the ability to dilute the vaccine making more doses available in the...” NCT00026611 ↗ |
| Modality | Vaccine | “control vaccine (DryVax)” NCT00000767 ↗ |
| Route | Other | “administered by the standard route of scarification” NCT00082446 ↗ |